Will FCX Benefit From Tariffs?
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Buy
64
NBIX Quote, Financials, Valuation and Earnings
Last price:
$133.55
Seasonality move
:
3.15%
Day range:
$131.07 - $134.25
52-week range:
$84.23 - $157.98
Dividend yield:
0%
P/E ratio:
44.49x
P/S ratio:
5.62x
P/B ratio:
5.12x
Volume:
629.5K
Avg. volume:
841.7K
1-year change:
-9.47%
Market cap:
$13B
Revenue:
$2.4B
EPS (TTM):
$2.95
Analysts' Opinion
-
Consensus RatingNeurocrine Biosciences has received a consensus rating of Buy. The company's average rating is a Buy based on 16 Buy ratings, 3 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $162.19, Neurocrine Biosciences has an estimated upside of 23.58% from its current price of $133.48.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $115.00 representing 12.37% downside risk from its current price of $133.48.
Fair Value
-
According to the consensus of 19 analysts, Neurocrine Biosciences has 23.58% upside to fair value with a price target of $162.19 per share.
NBIX vs. S&P 500
-
Over the past 5 trading days, Neurocrine Biosciences has overperformed the S&P 500 by 2.54% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Neurocrine Biosciences does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Neurocrine Biosciences has grown year-over-year revenues for 15 quarters straight. In the most recent quarter Neurocrine Biosciences reported revenues of $572.6M.
Earnings Growth
-
Neurocrine Biosciences earnings have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Neurocrine Biosciences reported earnings per share of $0.08.
Enterprise value:
12B
EV / Invested capital:
--
Price / LTM sales:
5.62x
EV / EBIT:
22.68x
EV / Revenue:
4.99x
PEG ratio (5yr expected):
0.93x
EV / Free cash flow:
24.47x
Price / Operating cash flow:
27.56x
Enterprise value / EBITDA:
21.53x
Gross Profit (TTM):
$2.4B
Return On Assets:
8.63%
Net Income Margin (TTM):
12.68%
Return On Equity:
12%
Return On Invested Capital:
11.76%
Operating Margin:
4.14%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $1.6B | $2B | $2.4B | $515.3M | $572.6M | |
| Gross Profit | $1.6B | $1.9B | $2.4B | $507.8M | $563.4M | |
| Operating Income | $275.6M | $470.4M | $501.4M | $105.3M | $23.7M | |
| EBITDA | $140.1M | $492.9M | $559.5M | $111.5M | $31.3M | |
| Diluted EPS | $0.60 | $3.63 | $2.95 | $0.42 | $0.08 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $1.1B | $1B | $1.4B | $1.8B | $1.6B | |
| Total Assets | $1.8B | $2.1B | $2.4B | $3.5B | $3.7B | |
| Current Liabilities | $190M | $253.5M | $374.1M | $712.9M | $522.9M | |
| Total Liabilities | $640.8M | $753.4M | $675.3M | $1.1B | $1.2B | |
| Total Equity | $1.2B | $1.4B | $1.7B | $2.4B | $2.5B | |
| Total Debt | $322M | $377.7M | $169.5M | $259M | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $254.7M | $645.4M | $529.9M | $130.3M | $64.8M | |
| Cash From Investing | -$187.6M | -$480M | -$57.6M | -$55M | $14.2M | |
| Cash From Financing | -$232.2M | $127M | -$674.5M | $69.9M | -$117.9M | |
| Free Cash Flow | $237.3M | $614.4M | $492.2M | $119.1M | $54.1M | |
NBIX
Sector
Market Cap
$13B
$34.5M
Price % of 52-Week High
83.07%
49.05%
Dividend Yield
0%
0%
Shareholder Yield
--
-1.01%
1-Year Price Total Return
-11%
-35.15%
Beta (5-Year)
0.243
0.615
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$132.30
200-day SMA
Buy
Level
$122.09
Bollinger Bands (100)
Buy
Level
105.35 - 126.99
Chaikin Money Flow
Buy
Level
1.9M
20-day SMA
Buy
Level
$129.16
Relative Strength Index (RSI14)
Buy
Level
62.24
ADX Line
Buy
Level
32.41
Williams %R
Neutral
Level
-44.6126
50-day SMA
Buy
Level
$124.70
MACD (12, 26)
Buy
Level
36.36
25-day Aroon Oscillator
Buy
Level
80
On Balance Volume
Neutral
Level
3.2M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (8.7914)
Buy
CA Score
(Annual)
Level (1.4729)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (4)
Buy
Ohlson Score
Level (-2.7049)
Buy
Piotroski F Score
(Annual)
Level (9)
Buy
Quality Ratio Score
Level (8)
Buy
Fundamental Score
Level (7)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
Stock Forecast FAQ
In the current month, NBIX has received 16 Buy ratings 3 Hold ratings, and 0 Sell ratings. The NBIX average analyst price target in the past 3 months is $162.19.
-
Where Will Neurocrine Biosciences Stock Be In 1 Year?
According to analysts, the consensus estimate is that Neurocrine Biosciences share price will rise to $162.19 per share over the next 12 months.
-
What Do Analysts Say About Neurocrine Biosciences?
Analysts are divided on their view about Neurocrine Biosciences share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Neurocrine Biosciences is a Sell and believe this share price will drop from its current level to $115.00.
-
What Is Neurocrine Biosciences's Price Target?
The price target for Neurocrine Biosciences over the next 1-year time period is forecast to be $162.19 according to 19 Wall Street analysts, 16 of them rate the stock a Buy, 0 rate the stock a Sell, and 3 analysts rate the stock a Hold.
-
Is NBIX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Neurocrine Biosciences is a Buy. 16 of 19 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of NBIX?
You can purchase shares of Neurocrine Biosciences via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Neurocrine Biosciences shares.
-
What Is The Neurocrine Biosciences Share Price Today?
Neurocrine Biosciences was last trading at $133.55 per share. This represents the most recent stock quote for Neurocrine Biosciences. Yesterday, Neurocrine Biosciences closed at $133.48 per share.
-
How To Buy Neurocrine Biosciences Stock Online?
In order to purchase Neurocrine Biosciences stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Can Levi Stock Double?
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
How High Can SharkNinja Stock Go?
If you know popular consumer appliance brands Shark and Ninja,…
Stock Ideas
Buy
70
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 58x
Buy
62
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
78
SBET alert for Jul 16
SharpLink Gaming [SBET] is up 28.58% over the past day.
Buy
75
MP alert for Jul 17
MP Materials [MP] is up 0.48% over the past day.
Sell
38
NAIL alert for Jul 17
Direxion Daily Homebuilders & Supplies Bull 3X Shs [NAIL] is up 2.38% over the past day.
